Rivaroxaban vs Dabigatran for Thromboprophylaxis After Joint-replacement Surgery: Exploratory Indirect Comparison Based on Meta-Analysis of Pivotal Clinical Trials
Authors:
- Vladimir TrkuljaVTVladimir Trkulja
- Robert KolundžićRKRobert Kolundžić
Open Access
- 1 April 2010
- journal article
- research article
- Published by Croatian Medical Journals in Croatian Medical Journal
- Vol. 51 (2) , 113-123
Abstract
To indirectly compare rivaroxaban and dabigatran for prevention of venous thromboembolism (VTE) after total hip or knee arthroplasty (THA, TKA) based on their pivotal efficacy/safety trials embracing a total of 20618 patients. Pooled risk differences (RD) for rivaroxaban vs enoxaparin and dabigatran vs enoxaparin obtained from separate meta-analyses of two sets of trials were used to indirectly estimate RDs for rivaroxaban vs dabigatran. Primary efficacy (any VTE+all-cause mortality) and safety (major bleeding) outcomes in enoxaparin arms largely differed across similarly designed rivaroxaban and dabigatran trials (differences in venography adjudication and bleeding events definitions). However, incidence of symptomatic VTE and incidence of major/non-major clinically relevant bleeding (including surgical site) were consistent in this respect. RDs (as percentages) for symptomatic VTE were: rivaroxaban-enoxaparin=-0.4% (95% confidence interval [CI], -0.9 to 0.05); dabigatran-enoxaparin=-0.09% (95% CI, -1.0 to 0.8); rivaroxaban-dabigatran=-0.3% (95% CI, -1.3 to 0.7; P=0.275). RDs for major/clinically relevant bleeding were rivaroxaban-enoxaparin=0.99% (95%CI, 0.29 to 1.69); dabigatran-enoxaparin=0.02% (95% CI, -1.0 to 1.0); rivaroxaban-dabigatran=0.97 (95% CI, -0.43 to 2.37; P=0.085). Mortality rates (all-cause, VTE-related, bleeding-related) were very low not indicating differences between any two of the three treatments. Methodological differences disable indirect comparisons of rivaroxaban vs dabigatran that would be based on major efficacy/safety outcomes of their pivotal trials. The two drugs do not seem to differ regarding incidence of symptomatic VTE. Risk of a relevant bleeding is higher with rivaroxaban than with enoxaparin and the same tendency exists also vs dabigatran. Direct rivaroxaban vs dabigatran comparisons in this setting are needed.Keywords
This publication has 19 references indexed in Scilit:
- A Cost-Effectiveness Model Comparing Rivaroxaban and Dabigatran Etexilate with Enoxaparin Sodium as Thromboprophylaxis after Total Hip and Total Knee Replacement in the Irish Healthcare SettingPharmacoEconomics, 2009
- Use of Emerging Oral Anticoagulants in Clinical PracticeAnnals of Surgery, 2009
- State-of-the-Art Review: Assessing the Safety Profiles of New Anticoagulants for Major Orthopedic Surgery ThromboprophylaxisClinical and Applied Thrombosis/Hemostasis, 2009
- Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviewsBMJ, 2009
- Postdischarge thromboprophylaxis and mortality risk after hip-or knee-replacement surgeryCanadian Medical Association Journal, 2008
- Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE‐MODEL randomized trialJournal of Thrombosis and Haemostasis, 2007
- Epidemiology of venous thromboembolism after lower limb arthroplasty: the FOTO studyJournal of Thrombosis and Haemostasis, 2007
- Association between asymptomatic deep vein thrombosis detected by venography and symptomatic venous thromboembolism in patients undergoing elective hip or knee surgeryJournal of Thrombosis and Haemostasis, 2007
- Interaction revisited: the difference between two estimatesBMJ, 2003
- Mortality after total hip replacement: 0-10-year follow-up of 39,543 patients in the Norwegian Arthroplasty RegisterActa Orthopaedica, 2000